



國藥集團
SINOPHARM
國藥控股股份有限公司
SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(於中華人民共和國註冊成立之股份有限公司，在香港以國控股份有限公司之名稱經營業務)
(Stock Code 股份代號：01099)

NOTIFICATION LETTER 通知信函

25 September 2023

Dear Non-Registered Shareholder (Note 1),

SINOPHARM GROUP CO. LTD.* (the "Company")
- NOTICE OF PUBLICATION OF 2023 INTERIM REPORT (the "Current Corporate Communication")

The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at sinopharm.todayir.com and the HKEXnews's website at www.hkexnews.hk. You may access the Current Corporate Communication on the Company's website, or browsing through the HKEXnews's website.

If you wish to receive the printed version of the current and all future Corporate Communications (Note 2) of the Company, please complete the Request Form (which may also be downloaded from the websites mentioned above) on the reverse side and send it to the Company c/o Computershare Hong Kong Investor Services Limited (the "H Share Registrar"), by using the pre-paid mailing label at the bottom of the Request Form (if you post in Hong Kong). Otherwise, please affix an appropriate stamp. The address of the H Share Registrar is 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong.

If for any reason you have difficulty in receiving or gaining access to the website version of the Current Corporate Communication, the Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

Should you have any queries relating to any of the above matters, please call the Company's enquiry hotline at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays.

Yours faithfully,
For and on behalf of
Sinopharm Group Co. Ltd.*
Yu Qingming
Chairman

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."

Note 1: This letter is being sent to the non-registered holders of the H shares of the Company, whose shares are held in the Central Clearing and Settlement System (CCASS) and who have notified the Company through Hong Kong Securities Clearing Company Limited that they wish to receive the Company's Corporate Communications. If you have sold or transferred all your shares in the Company, please disregard this letter and the Request Form on its reverse side.

Note 2: Corporate Communication (the "Corporate Communication") of the Company refers to any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the annual report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

致非登記股份持有人(附註1)：

國藥控股股份有限公司(「本公司」)
- 2023年中期報告(「本次公司通訊」)之發佈通知

本公司的本次公司通訊中、英文版本已上載於本公司網站 sinopharm.todayir.com 及香港交易所披露易網站 www.hkexnews.hk，歡迎瀏覽。請在本公司網站，或在香港交易所披露易網站瀏覽有關文件。

如閣下欲收取本公司本次及將來所有公司通訊(附註2)之印刷本，請填妥在本信函背面的申請表格(該表格亦可於上述網站下載)，並使用申請表格下方的預付費郵寄標籤寄回(如在香港投寄)；否則，請貼上適當的郵票。申請表格請經香港中央證券登記有限公司(「H股登記處」)寄回本公司，H股登記處的地址為香港灣仔皇后大道東183號合和中心17M樓。

如閣下因任何理由以致在收取或閱覽本次公司通訊之網上版本時出現困難，本公司將在閣下提出要求後立即免費向閣下寄上本次公司通訊的印刷版本。

如閣下對本信函內容有任何疑問，請致電本公司電話查詢熱線(852) 2862 8688，辦公時間為星期一至五(公眾假期除外)上午9時正至下午6時正。

代表國藥控股股份有限公司
董事長
于清明
謹啟

2023年9月25日

* 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港公司。

附註1：本信函收件對象為本公司非登記H股股份持有人。該等人士的股份存放於中央結算及交收系統(中央結算系統)，並且他們已經通過香港中央結算有限公司通知本公司，希望收到本公司公司通訊。如果閣下已出售或轉讓全部所持有的本公司股份，則無需要理會本信函及其背面的申請表格。

附註2：本公司公司通訊(「公司通訊」)指本公司發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於：(a)年度報告及財務摘要報告(如適用)；(b)中期報告及中期摘要報告(如適用)；(c)會議通告；(d)上市文件；(e)通函；及(f)委任代表表格。

**Request Form 申請表格**

To: **Sinopharm Group Co. Ltd.** (the “Company”)
(Stock Code: 01099)
c/o Computershare Hong Kong Investor Services Limited
(the “H Share Registrar”)
17M Floor, Hopewell Centre,
183 Queen’s Road East,
Wanchai, Hong Kong

致：**國藥控股股份有限公司**（「本公司」）
(股份代號：01099)
經香港中央證券登記有限公司
(「H 股登記處」)
香港灣仔皇后大道東 183 號
合和中心 17M 樓

I/We would like to receive the **CURRENT & ALL FUTURE** Corporate Communications of the Company in the manner as indicated below:
本人/我們現在希望以下列方式收取本公司**本次及將來**所有公司通訊：

(Please mark **ONLY ONE (X)** of the following boxes) (請從下列選擇中，僅在其中**一個空格**內劃上「X」號)

- to receive a printed notification letter informing that the Corporate Communications have been published on the Company’s website sinopharm.todayir.com and read the Corporate Communications published on the Company’s website (the “Website Version”) instead of receiving printed copies; **OR**
收取有關公司通訊已在本公司網站 sinopharm.todayir.com 刊發之通知信函並在本公司網站上瀏覽公司通訊(「網上版本」)，以代替印刷本；**或**
- to receive the printed copies of all Corporate Communications in both English and Chinese versions; **OR**
收取所有公司通訊之中、英文印刷本；**或**
- to receive the printed copies of all Corporate Communications in English version only; **OR**
僅收取所有公司通訊之英文印刷本；**或**
- to receive the printed copies of all Corporate Communications in Chinese version only.
僅收取所有公司通訊之中文印刷本。

Name(s)[#]
姓名[#]

Signature
簽名

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Address[#]
地址[#]

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Contact telephone number
聯絡電話號碼

Date
日期

You are required to fill in the details if you download this Request Form from the Company’s Website. 假如你從本公司網站下載本申請表格，請必須填上有關資料。

Notes 附註：

- Please complete all your details clearly.
請 閣下清楚填妥所有資料。
- By electing to read the Website Version of the Corporate Communications published on the Company’s website in place of receiving printed copies, you have expressly consented to waive the right to receive the Corporate Communications in printed form.
在選擇瀏覽在本公司網站刊發之公司通訊網上版本以代替收取印刷本後，閣下已明示同意放棄收取公司通訊印刷本的權利。
- This Request Form is to be completed by the non-registered holders of the H shares of the Company, whose shares are held in the Central Clearing and Settlement System (CCASS) and who have notified the Company through Hong Kong Securities Clearing Company Limited that they wish to receive the Company’s Corporate Communications.
本申請表格應由本公司非登記 H 股股份持有人填寫。該等人士的股份存放於中央結算及交收系統(中央結算系統)，並且他們已經通過香港中央結算有限公司通知本公司，希望收到本公司公司通訊。
- Any form with more than one box marked (X), with no box marked (X), with no signature or otherwise incorrectly completed shall be void.
如在本表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確，則本表格將會作廢。
- The above instruction will apply to the **CURRENT & ALL FUTURE** Corporate Communications of the Company to be sent to you until you notify the Company c/o the H Share Registrar, Computershare Hong Kong Investor Services Limited, to the contrary or unless you have at anytime ceased to have any shareholding in the Company.
上述指示適用於本公司**本次及將來**發送予閣下之所有公司通訊，直至閣下通知本公司經 H 股登記處香港中央證券登記有限公司另外之安排或閣下在任何時候停止持有本公司的任何股份。
- For the avoidance of doubt, we do not accept any special instructions written on this Request Form.
為免存疑，任何寫在本申請表格上的額外指示，本公司將不予接受。
- You are entitled to change the choice of language or means of receipt of the Company’s Corporate Communications at any time by reasonable notice in writing or by email to the Company c/o the H Share Registrar at sinopharm.ecom@computershare.com.hk.
閣下有權隨時發出合理時間的書面通知或電郵到 sinopharm.ecom@computershare.com.hk 通過 H 股登記處予本公司，要求更改本公司公司通訊之語言版本或收取方式。

The Current Corporate Communication of the Company refers to 2023 Interim Report.

本申請表格所提及之本公司本次公司通訊指 2023 年中期報告。

*The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”

本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香港公司。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited
香港中央證券登記有限公司
Freepost No. 簡便回郵號碼：37
Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this Request Form to us.

No postage is necessary if posted in Hong Kong.

當 閣下寄回本申請表格時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。

Get in touch with us 與我們聯繫

Send us an enquiry 查詢
Rate our service 評價
Lodge a complaint 投訴



Contact Us 聯繫我們

www.computershare.com/hk/contact